HG-67PRECLINICAL EFFICACY OF ALK2 INHIBITORS IN ACVR1 MUTANT DIPG
Diana Carvalho(Institute of Cancer Research), Chris Jones(North Carolina State University), Sue Eccles(Institute of Cancer Research), Valeria Molinari(Institute of Cancer Research), Andrew S. Moore(Children's Health Queensland Hospital and Health Service), Maria Cristina Vinci(Institute of Cancer Research), Albert Hallsworth(Institute of Cancer Research), Liam Hudson(Institute of Cancer Research), Florence I. Raynaud(Institute of Cancer Research), Ruth Ruddle(Institute of Cancer Research), Angela Hayes(Institute of Cancer Research), Alan T. Henley(Institute of Cancer Research), Swen Hoelder(Institute of Cancer Research), Alan Mackay(Institute of Cancer Research), Nagore G. Olaciregui(Sant Joan de Déu Research Foundation), Paul E. Brennan(Discovery Centre), Alex N. Bullock(Discovery Centre), Melanie Valenti(Institute of Cancer Research), Ángel M. Carcaboso(Hospital Sant Joan de Déu Barcelona), Sergey Popov(Heidelberg University), Kathryn R. Taylor(Stanford University), Alexis de Haven Brandon(Institute of Cancer Research), Aïcha Boudhar(University of Oxford)
Cited by 1
Related Papers
Guidelines for the welfare and use of animals in cancer research
|British Journal of Cancer|2010|1.4k
Targetable Kinase-Activating Lesions in Ph-like Acute Lymphoblastic Leukemia
|New England Journal of Medicine|2014|1.4k
Integrated Molecular Meta-Analysis of 1,000 Pediatric High-Grade and Diffuse Intrinsic Pontine Glioma
|Cancer Cell|2017|1.3k
The promise and peril of chemical probes
|Nature Chemical Biology|2015|848